Clinical Trial Detail

NCT ID NCT02568267
Title Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Ignyta, Inc.
Indications

non-small cell lung carcinoma

Advanced Solid Tumor

colorectal cancer

anaplastic large cell lymphoma

Therapies

Entrectinib

Age Groups: adult

Additional content available in CKB BOOST